Aleš Ambrožič

Dr. Aleš Ambrožič

University Medical Center Ljubljana
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2002 in International Immunology
Verified
Journal Article
Open access
PDF file
AAAleš Ambrožič
Aleš Ambrožič
TATadej Avičin
Tadej Avičin
KIKenji Ichikawa
Kenji Ichikawa
TKTanja Kveder
Tanja Kveder
EMEiji Matsuura
Eiji Matsuura
TKTakao Koike
Takao Koike
β2‐Glycoprotein I (β2GPI) appears to be the major antigen for antiphospholipid antibodies (aPL) in patients with antiphospholipid syndrome (APS). In early infancy, virtually all children initiate transient immune response to non‐pathogenic nutritional antigens, which fails to terminate in children with atopic diseases. To examine the possibility that a prolonged immune response to β2GPI could also spread to the human protein, antibodies against human β2GPI (anti‐β2GPI) were determined in 93 randomly selected children with different allergic diseases. A high frequency (42%) of IgG anti‐β2GPI was found in children with atopic dermatitis (AD), but not in those with other allergic diseases. Anti‐β2GPI in children with AD were exclusively of the IgG1 subclass and bound to bovine β2GPI as well, but not to either β2GPI combined with the phospholipid cardiolipin. The epitopes were identified in domain V of β2GPI and the antibody binding was abolished upon the specific proteolytic cleavage of the phospholipid‐binding C‐terminal loop in domain V of β2GPI. These results indicated that the epitopes for anti‐β2GPI in children with AD most likely resided in close vicinity of the phospholipid‐binding site of β2GPI. The epitopic difference from anti‐β2GPI in APS may explain presumed non‐thrombogenicity of anti‐β2GPI in children with AD.

13 May 2020 in Cells
Verified
Journal Article
Open access
PDF file
USUla Stok
Ula Stok
EBElizabeta Blokar
Elizabeta Blokar
MLMetka Lenassi
Metka Lenassi
MHMarija Holcar
Marija Holcar
MFMojca Frank-Bertoncelj
Mojca Frank-Bertoncelj
Polona ŽigonPolona Žigon
Polona Žigon
Antiphospholipid syndrome (APS) is a systemic autoimmune disease, characterized by thrombosis, obstetric complications and the presence of antiphospholipid antibodies (aPL), which drive endothelial injury and thrombophilia. Extracellular vesicles (EVs) have been implicated in endothelial and thrombotic pathologies. Here, we characterized the quantity, cellular origin and the surface expression of biologically active molecules in small EVs (sEVs) isolated from the plasma of thrombotic APS patients (n = 14), aPL-negative patients with idiopathic thrombosis (aPL-neg IT, n = 5) and healthy blood donors (HBD, n = 7). Nanoparticle tracking analysis showed similar sEV sizes (110–170 nm) between the groups, with an increased quantity of sEVs in patients with APS and aPL-neg IT compared to HBD. MACSPlex analysis of 37 different sEV surface markers showed endothelial (CD31), platelet (CD41b and CD42a), leukocyte (CD45), CD8 lymphocyte and APC (HLA-ABC) cell-derived sEVs. Except for CD8, these molecules were comparably expressed in all study groups. sEVs from APS patients were specifically enriched in surface expression of CD62P, suggesting endothelial and platelet activation in APS. Additionally, APS patients exhibited increased CD133/1 expression compared to aPL-neg IT, suggesting endothelial damage in APS patients. These findings demonstrate enhanced shedding, and distinct biological properties of sEVs in thrombotic APS.

10 January 2012 in Lupus
Verified
Journal Article
Closed access
PDF file
KPK Perdan-Pirkmajer
K Perdan-Pirkmajer
GTGerhard G. Thallinger
Gerhard G. Thallinger
NSN Snoj
N Snoj
SČS Čučnik
S Čučnik
PŽP Žigon
P Žigon
AAAleš Ambrožič
Aleš Ambrožič
Vaccines have undoubtedly brought overwhelming benefits to mankind and are considered safe and effective. Nevertheless, they can occasionally stimulate autoantibody production or even a recently defined syndrome known as autoimmune/inflammatory syndrome induced by adjuvants (ASIA). There is scarce data regarding autoimmune response after seasonal/influenza A (H1N1) vaccine in patients with autoimmune inflammatory rheumatic disease (AIRD). The objective of our study was therefore to determine autoimmune response in a large group of AIRD patients vaccinated against seasonal and/or H1N1 influenza. We conducted a prospective cohort study with a 6-month follow-up. Two-hundred and eighteen patients with AIRD (50 vaccinated against seasonal influenza, six against H1N1, 104 against both, 58 non-vaccinated controls) and 41 apparently healthy controls (nine vaccinated against seasonal influenza, three against H1N1, 18 against both, 11 non-vaccinated controls) were included. Blood samples were taken and screened for autoantibodies [antinuclear antibody (ANA), anti-extractable nuclear antigen (anti-ENA), anticardiolipin (aCL) IgG/IgM antibodies, anti-beta 2-glycoprotein I (anti-β2GPI)] at inclusion in the study, before each vaccination, 1 month after the last vaccination and 6 months after inclusion. For non-vaccinated participants (patients and healthy controls) blood samples were taken at the time of inclusion in the study and 6 months later. We report that after the administration of seasonal/H1N1 vaccine there were mostly transient changes in autoantibody production in AIRD patients and in healthy participants. However, a small subset of patients, especially ANA-positive patients, had a tendency towards anti-ENA development. Although no convincing differences between the seasonal and H1N1 vaccines were observed, our results imply that there might be a slight tendency of the H1N1 vaccine towards aCL induction. Although seasonal and H1N1 vaccines are safe and effective, they also have the potential to induce autoantibodies in selected AIRD patients and healthy adults. Follow-up of such individuals is proposed and further research is needed.

6 January 2012 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
KLKatja Lakota
Katja Lakota
GTGerhard G. Thallinger
Gerhard G. Thallinger
SSSnežna Sodin-Šemrl
Snežna Sodin-Šemrl
BRBlaz Rozman
Blaz Rozman
AAAleš Ambrožič
Aleš Ambrožič
TKTanja Kveder
Tanja Kveder
Introduction: An international cohort study of 73 anti-Ku-positive patients with different connective tissue diseases was conducted to differentiate the anti-Ku-positive populations of patients based on their autoantibody profile and clinical signs/symptoms and to establish possible correlations between antibodies against Ku p70 and Ku p80 with autoimmune diseases. Methods: Sera of anti-Ku-positive patients were collected from six European centers and were all secondarily tested (in the reference center); 73 were confirmed as positive. Anti-Ku antibodies were detected with counter-immunoelectrophoresis (CIE), line immunoassay (LIA), and immunoblot analyses. All clinical and laboratory data were follow-up cumulative data, except for anti-Ku antibodies. Statistical analyses were performed by using R (V 2.12.1). The Fisher Exact test was used to evaluate the association between anti-Ku antibodies and diagnosis, gender, clinical signs, and other observed antibodies. The P values were adjusted for multiple testing. Separation of disease populations based on the presence of antibodies and clinical signs was investigated by principal-components analysis, which was performed by using thr// R's prcomp function with standard parameters. Results: A 16% higher prevalence of anti-Ku p70 was found over anti-Ku p80 antibodies. In 41 (57%) patients, a combination of both was detected. Five (7%) patients, who were CIE and/or LIA anti-Ku positive, were negative for both subsets, as detected with the immunoblot; 31% of the patients had undifferentiated connective tissue disease (UCTD); 29% had systemic sclerosis (SSc); 18% had systemic lupus erythematosus (SLE); 11% had rheumatoid arthritis; 7% had polymyositis; and 3% had Sjögren syndrome. Conclusions: A significant positive association was found between female patients with anti-Ku p70 and joint/bone features, and a significant negative association was found between female patients with anti-Ku p80 only and joint/bone features (P = 0.05, respectively). By using the first and the third components of the principal-component analysis (PCA) with 29 parameters evaluated, we observed that the anti-Ku-positive population of UCTD patients had overlapping parameters, especially with SLE, as opposed to SSc, which could be helpful in delineating UCTD patients.

4 January 2016 in Scandinavian Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
KPK Perdan-Pirkmajer
K Perdan-Pirkmajer
Sergej PirkmajerSergej Pirkmajer
Sergej Pirkmajer
MTM Thevis
M Thevis
ATA Thomas
A Thomas
SPS Praprotnik
S Praprotnik
AAAleš Ambrožič
Aleš Ambrožič
Objectives: The mechanism by which methotrexate (MTX) improves glucose homeostasis in patients with rheumatoid (RA) and psoriatic arthritis (PsA) remains undetermined. Animal studies indicate a role for intracellular accumulation of 5-aminoimidazole-4-carboxamide-1-β-d-ribofuranosyl 5ʹ-monophosphate (ZMP) but this has not been directly demonstrated in humans. We explored whether accumulation of ZMP is associated with improvements in glucose homeostasis during MTX therapy. Method: MTX-naïve, non-diabetic RA (n = 16) and PsA (n = 10) patients received uninterrupted MTX treatment for 6 months. To evaluate whether ZMP accumulated during MTX therapy, we measured the concentration of ZMP in erythrocytes and the concentration of its dephosphorylated derivative 5-aminoimidazole-4-carboxamide-1-β-d-ribofuranoside (AICAR) in urine using liquid chromatography mass spectrometry (LC-MS/MS). To assess glucose homeostasis, we determined the concentration of glycated haemoglobin (HbA1c) and homeostasis model assessment of insulin resistance [HOMA-IR: fasting glucose (mmol/L) × fasting insulin (μU/mL)/22.5]. Results: Erythrocyte ZMP and urinary AICAR concentrations did not increase during 6 months of MTX therapy. HbA1c concentration was reduced from 5.80 ± 0.29% at baseline to 5.51 ± 0.32% at 6 months (p < 0.001), while HOMA-IR remained unaltered. Reduction in HbA1c concentration was not associated with increased ZMP or AICAR concentrations. Conclusions: MTX therapy probably does not produce a chronic increase in erythrocyte ZMP or urinary AICAR concentrations. Collectively, our data do not support the hypothesis that MTX improves glucose homeostasis through chronic accumulation of ZMP.

1 April 2005 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
AAAleš Ambrožič
Aleš Ambrožič
BBBorut Božič
Borut Božič
TKTanja Kveder
Tanja Kveder
JMJanja Majhenc
Janja Majhenc
VAVesna Arrigler
Vesna Arrigler
BRBlaž Rozman
Blaž Rozman